Loading
Loading
Research Overview
Khavinson tetrapeptide (Ala-Glu-Asp-Leu) targeted at bronchial and lung tissue; proposed to stimulate repair and regeneration of respiratory epithelium and modulate inflammatory signalling in pulmonary tissue.
Bronchogen is a short, synthetic tetrapeptide composed of the amino acid sequence Ala–Glu–Asp–Leu (AEDL) that has been investigated as a tissue-specific bioregulatory peptide associated with bronchial and lung tissues. It belongs to a broader class of organ-derived peptides originally identified through fractionation of animal tissue extracts and subsequently synthesized for experimental research. This class of compounds was developed to address limitations observed in age- and stress-related decline in endogenous regulatory signaling within specific tissues.
Bronchogen was originally isolated from bronchial epithelial tissue and studied for its potential role in maintaining structural and molecular homeostasis of the respiratory epithelium in experimental systems. Preclinical investigations have focused on its interactions with lung epithelial cells, immune cell populations, and intracellular regulatory mechanisms involved in gene expression and tissue maintenance. The peptide’s small size and defined structure allow it to be synthesized reproducibly and evaluated across a range of in vitro and animal models.
Experimental studies in cell cultures and rodent models have reported that Bronchogen exposure is associated with changes in bronchial epithelial differentiation markers, mucin gene expression, and signaling pathways involved in inflammatory regulation. In animal models of chemically induced lung injury and obstructive pathology, Bronchogen administration coincided with alterations in airway epithelial structure, immune cell profiles, and local immune mediators relative to untreated controls. These observations have been examined alongside molecular data suggesting interactions with nuclear components such as DNA and histone proteins, indicating a possible role in epigenetic and transcriptional regulation under experimental conditions.
All findings related to Bronchogen are derived exclusively from preclinical research, including in vitro assays and animal studies. Bronchogen is not approved for human use, and no clinical trials have evaluated its safety, efficacy, or pharmacokinetics in humans. Current interest in Bronchogen reflects its utility as an investigational tool for studying lung-specific regulatory peptides and mechanisms of respiratory tissue maintenance in experimental systems.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, bronchogen has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Bronchogen research is most relevant to protocols examining:
Pulmonary and bronchial tissue repair research
Respiratory epithelium regeneration studies
Age-related lung decline investigations
Researchers studying organ-targeted bioregulator peptides
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Khavinson tetrapeptide (Ala-Glu-Asp-Leu) targeted at bronchial and lung tissue; proposed to stimulate repair and regeneration of respiratory epithelium and modulate inflammatory signalling in pulmonary tissue.
| Parameter | Value |
|---|---|
| Dose range | 10–20 mg/day (cycled) |
| Schedule | Daily (cycled) |
| Route | Subcutaneous |
| Half-life | ~Hours |
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.